April 3, 2012
at MONTCLAIR STATE UNIVERSITY
1 Normal Avenue
Montclair, New Jersey 07043
“I’m grateful for everyday.” –Jay Russell
I’m making every day count. Jay was lucky to know from childhood that he wanted to be an actor. But when he was diagnosed with cancer, he feared losing all of his dreams. He endured 10 months of chemotherapy, radiation and surgery. It was a very scary, dark time for him—like an endless night. With the help of his doctors and support from his family, Jay is now back to acting and doing the things he loves. At Bristol-Myers Squibb we believe that the will of the patient, matched by our desire to find innovative medicines, can make all the difference. For more about Jay and others who are prevailing over serious disease, visit www.bms.com.
Wee ar W aree proud proud to suppor supportt the 2012 PharmF PharmFest Fest es at Montc est Montclair lair State Univer University. sityy.
8:00 a.m. 8:30 a.m.
Program Schedule University Hall Conference Center – 7th Floor
OPENING REMARKS Mr. Dean J. Paranicas President and CEO, HealthCare Institute of New Jersey The Honorable Kim Guadagno Lt. Governor and Secretary of State, State of New Jersey
OPENING SESSION: Overcoming Today’s Pharma Challenge: Building on Past Successes with a Focus on Science, People, and Partnerships MODERATOR: Dr. Francis Cuss
Senior Vice President, Research, R&D, Bristol-Myers Squibb
PANELISTS: Mr. Paul Biondi Dr. Donald Nicholson Dr. Maria Webb
Senior Vice President, R&D Operations, Bristol-Myers Squibb Vice President, Worldwide Discovery, Merck Chief Scientific Officer, Venenum Biodesign
10:00 a.m. SESSION A-1:
Start-up Enterprises and the Pharmaceutical Sector: Challenges and Innovations in Today’s Marketplace
MODERATOR: Ms. Jeanmarie Tenuto
CEO, Healthcare Technical Solutions, LLC
PANELISTS: Dr. Michel M. Bitritto Dr. Sri P. Srivastava
Director, New Jersey Meadowlands Commission Business Accelerator Managing Partner, ClinTech Research, LLC
Mr. Wayne Wong
Senior President for Business Development, Nuclear Diagnostic Products
The Convergence of the Biotech, Pharma, Medical Devices, and Diagnostics Industries: Challenges and Opportunities
Mr. Christopher Bowe
US Healthcare Analyst, Scrip Intelligence
Dr. Samir Tari Dr. Pascal Yvon
Founder, PCAsso Diagnostics President, BioSciences Expansion
11:30 a.m. LUNCH (Hosted by The Margaret and Herman Sokol Institute for Pharmaceutical Life Sciences) Welcoming Remarks: Dr. Susan Cole
President, Montclair State University
Keynote Address: Mr. Robert Hugin
President and Chief Executive Officer Celgene Corporation
The Changing Landscape 1:00 p.m.
Chair, Department of Marketing, School of Business, Montclair State University
PANELISTS: Mr. Brian Cain Mr. Jerry Clor Mr. Norman Tessell Mr. David Thompson
Vice President of Global Market Research & Analytics, Merck Bio/Pharma Industry Consultant Director of Business Development, Imaging Systems, Atlantis Worldwide President, KnowledgePoint360 Group
New Trends in Pharmaceutical Sales and Market Research
MODERATOR: Dr. Avinandan Mukherjee
Computational Drug Design
MODERATOR: Dr. Terry Stouch
President, Science for Solutions
PANELISTS: Dr. Kalyan Das Dr. Sung-Sau So Dr. Sidney Topiol
Research Professor, Center for Advanced Biotechnology and Medicine Rutgers University Principal Scientist, Computational Chemistry and Datamining Group, Roche President, 3D-2Drug
Drilling Down: New Jerseyâ€™s Life Sciences Vendor Community
Mr. Dean J. Paranicas
President and CEO, HealthCare Institute of New Jersey
Mr. Mike Loftus Mr. Cornell Stamoran Mr. Alan Vernon
Director, Business Development, Integrium Clinical Research Vice President of Corporate Development and Strategy, Catalent Vice President, Translation Plus
Small Molecule and Biologic Drug Discovery and Development
Dr. David Rotella
Sokol Professor of Chemistry, College of Science and Mathematics, Montclair State University
Dr. William J. Greenlee Dr. David Kimbal Dr. Suzanne J. Suchard Dr. Robert Veneziale
Medicinal Chemistry Consultant Research Professor, Rutgers University School of Pharmacy Research Fellow in Immunology Drug Discovery, Bristol-Myers Squibb Associate Research Fellow, Drug Safety, Pfizer Global Research and Development
Career Success in the Changing Pharma Industry
Ms. Barbara White
Principal, Transformation Coaching and Consulting, LLC
Mr. Terence J. Gunning Ms. Cheryl Maiello Ms. Heidi Pfefferkorn Ms. MaryLinda Schumann Dr. Maria Webb
Chief Operating Officer, MedLabs Diagnostics Staffing Manager, Global Development, Novartis Director, Regulatory Chemistry, Manufacturing and Controls, Novartis Internship Program Recruiter, Chemetall Chief Scientific Officer, Venenum Biodesign
Committed to improving the lives of patients worldwide 速
Celgene is proud to support PharmFest 2012 at Montclair State University
Panel Session Descriptions Opening Session:
Overcoming Today’s Pharma Challenge: Building on Past Successes with a Focus on Science, People, and Partnerships
The Convergence of the Biotech, Pharma, Medical Devices, and Diagnostics Industries: Challenges and Opportunities
The past several years have brought many economic and regulatory changes that have impacted the pharmaceutical industry, resulting in mergers and acquisitions, reduced provider interactions, and increased market competition from generic drug companies. At the same time, the industry as a whole has faced the challenge of adapting to multiple patent expirations, which potentially profoundly influence investor decisions, placing additional pressure on the developing drug pipelines of many Pharma companies.
As the traditional ‘Big Pharma’ companies consider their business model and look to collaborate with biotechnology, medical device, and diagnostics companies, and in some cases consider generics and biosimilars as strategies for profitability and growth, the lines are becoming increasingly blurred. With this development come challenges and opportunities. This panel will discuss what that means to these various industries and the future of innovation.
It takes a minimum of 10-15 years of rigorous science to develop a single drug from discovery to launch, and the inherent risk is critically significant with only about 25 drug approvals annually by the Federal Drug Administration in the United States. Not surprisingly, as an industry we focus on our recent filings and approvals, but important adaptations have taken place that build upon the industry’s earlier successes. These continue to positively impact world health and improve the lives of patients and their families. Today, this panel will explore how our industry is building on these past successes: by focusing on innovations in science and technology, creating work cultures that foster collaborative leadership, and partnering across academia and biotech companies to move drug discovery forward to improve health and prevent diseases.
Session A-1: Start-up Enterprises and the Pharmaceutical Sector: Challenges and Innovations in Today’s Marketplace Start-up entities remain essential in ensuring the long-term innovation and competitiveness of the biotechnology and pharmaceutical industries in New Jersey and the region. The risks and rewards of start-up enterprises are, in many ways, magnified in the pharmaceutical technology sector. In addition to the actual technology and the associated business model that an enterprise seeks to exploit, access to capital, information asymmetry, knowledge transferability, and intellectual property issues represent unique challenges and opportunities for the biotech entrepreneur. This panel session will address the critical role that life science start-ups represent in the biotech value chain and will consider the ways in which public and private sector entities are seeking to support and strengthen these enterprises.
Session B-1: New Trends in Pharmaceutical Sales and Market Research The pharmaceutical sales and marketing landscape has changed dramatically over the past few years with emerging biotech products, new technology proliferation, greater cost consciousness, and increased global sales of pharmaceuticals. At the center of this highly regulated industry emerges an increase of communications, digital marketing efforts, social media, and sales force success strategies. Pharmaceutical marketing is heavily centered on new trends in sales management and market research. This panel session will discuss some of the emerging trends in this area, such as the use of sales technologies, direct-to-consumer and direct-to-physician marketing communications, use of multimedia, social media and virtual communities, electronic detailing, prescription data mining, and cloud computing. Opportunities created by these trends in terms of more targeted marketing, customized sales solutions, intelligent sales support systems, and cost savings, as well as challenges such as data privacy and security issues, re-training for salespersons, and effective measurement of ROI will be discussed.
Session B-2: Computational Drug Design The pharmaceutical industry is faced with a never-ending need for streamlining the drug discovery process. Technologies need to be identified and developed which allow for the rapid identification of lead drug candidates, such as computational approaches. This panel will examine the current status of computational drug discovery technology and its application to the rapid identification of drug leads.
Panel Session Descriptions Session C-1: Drilling Down: New Jersey’s Life Sciences Vendor Community Over the past 100 years, as New Jersey’s life sciences industry has grown into the greatest cluster of pharmaceutical, biotech, and medical technology companies in the world, a comprehensive support system of specialized vendors, providing goods and services to the industry, has also evolved. Ranging from glass manufacturers to marketers to patent attorneys, these vendors comprise the infrastructure that New Jersey’s life sciences companies have come to rely on. This panel will examine the critical role these vendors play in the industry and their future role in the changing life sciences business model.
Session C-2: Small Molecule and Biologic Drug Discovery and Development In recent years, the discovery and development of biologics such as monoclonal antibodies and vaccines has assumed an increasing importance in the portfolio of pharmaceutical companies. The range of therapeutic applications for large molecules is also growing as the field expands. Small molecule drug discovery remains an essential
component of drug discovery and development. This panel session will provide perspectives on the relative advantages and disadvantages of each approach in terms of discovery, development, and therapeutic utility for small and large molecules. It will also highlight key differences and points of overlap between these two areas of pharmaceutical research and drug discovery.
Session D: Career Success in the Changing Pharma Industry A panel of Montclair State University alumni will share information about their careers and offer advice to assist those who are interested in pursuing careers in the pharmaceutical industry. As Montclair State graduates of various majors, the panelists will focus on the wide variety of professional opportunities in Pharma that extend beyond the traditional perception of researchers in lab coats. These alumni have experiences that demonstrate that the industry includes opportunities not only in drug development and manufacturing, but also in management, production, sales, quality control, marketing, accounting, IT, Human Resources, etc.. The career information and the discussion will be extremely helpful to Montclair State students as they consider how to pursue their career goals as graduates and the potential for employment in the industry.
Sanofi congratulates Montclair State University’s College of Science and Mathematics, the School of Business, and the HealthCare Institute of New Jersey for once again presenting PharmFest, the state’s leading industry/academic forum on emerging issues and trends in pharmaceutical life sciences.
New Jersey: The home of life sciences innovation... Discovering the cures and treatments of tomorrow. Creating economic growth and jobs. Improving health around the world.
ADVANCING GLOBAL HEALTH LEADING NEW JERSEY’S ECONOMY 120 Albany St., Tower 1, Suite 505 New Brunswick, NJ 08901 732-729-9619 • www.hinj.org
KIM GUADAGNO Lt. Governor and Secretary of State State of New Jersey
DEAN J. PARANICAS
Kim Guadagno was elected New Jersey’s first Lieutenant Governor in November 2009. As Governor Chris Christie’s running mate, she was sworn into office on January 19, 2010. In addition to serving as the Lt. Governor, Kim Guadagno serves as the 33rd Secretary of State.
Dean J. Paranicas became the third president and CEO of the HealthCare Institute of New Jersey (HINJ) in March, 2011. Prior to joining HINJ, Mr. Paranicas was Vice President, Corporate Secretary and Public Policy for BD. Starting as BD’s Associate General Counsel and Assistant Secretary in 1981, he later served as Director, Corporate Development and Strategic Investments, as Director, Investor Relations, and Vice President, Investor Relations and Public Affairs.
As Lt. Governor, Kim Guadagno has led the Christie Administration’s efforts to improve New Jersey’s economic vitality, to streamline government, and to make business feel welcome again in New Jersey. The Lt. Governor chairs the Red Tape Review Commission, which is engaged in an ongoing review and reform of the State’s regulatory process. In her first year in Office, the state saw a 66% decrease in the number of proposed regulations over the same period the year before. Guadagno also operates the Business Action Center, which is a one-stop shop for business retention, attraction, and expansion. As Secretary of State, Guadagno is the State’s chief election official, oversees promotion of New Jersey’s $38 billion tourism industry, and administers programs related to the arts, culture, and history. Lt. Governor Guadagno has been a lawyer for more than 28 years and began her career in public service as a federal prosecutor with the Organized Crime and Racketeering Strike Force in Brooklyn, New York. Guadagno was born in Waterloo, Iowa and is a cum laude graduate of Ursinus College in Collegeville, Pennsylvania. She received her juris doctorate degree, cum laude, from the American University Washington College of Law in Washington, D.C. Lt. Governor Guadagno and her husband, Superior Court Judge Michael Guadagno, currently reside in Monmouth Beach with their three sons.
President and CEO HealthCare Institute of New Jersey
Mr. Paranicas began his career as an associate attorney with McCarter & English, LLP in Newark, New Jersey. He earned a BA degree with honors from Rutgers College, Rutgers University, where he was a member of Phi Beta Kappa. He earned a JD degree from Rutgers-Newark School of Law, where he was an Editor of the Rutgers Law Review. Mr. Paranicas previously served as HINJ’s Board Secretary and Chair of its Steering Committee. He is a member of the Board of Directors of the New England Healthcare Institute (NEHI). He is also Chair of the Board of Trustees of the Foundation for New Jersey Public Broadcasting. He is a former member of the Rutgers University Board of Governors and the Rutgers University Foundation Board of Overseers. He is also a former Chair of the Rutgers University Board of Trustees, where he is now a Trustee Emeritus.
ROBERT J. HUGIN President and CEO Celgene Corporation
SUSAN A. COLE President Montclair State University
Dr. Susan A. Cole assumed office in September of 1998 as the eighth president of Montclair State University, which is the second largest university in New Jersey, with 18,500 graduate and undergraduate students. Dr. Cole served as President of Metropolitan State University in Minneapolis/St. Paul, Minnesota from 1993 to 1998 and, prior to that, as Vice President for University Administration and Personnel at Rutgers, The State University of New Jersey, Associate University Dean for Academic Affairs at Antioch University, and a faculty member at The City University of New York.
Mr. Robert J. Hugin serves as Chairman and Chief Executive Officer of Celgene Corporation, a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for unmet medical needs in cancer and immuneinflammatory disease. He joined Celgene in June 1999 and has been a Director of Celgene since December 2001. Mr. Hugin also serves as a Director of The Medicines Company, Atlantic Health System, Inc. and of Family Promise, a national non-profit network assisting homeless families. He serves as Treasurer of The Pharmaceutical Research and Manufacturers of America and is a member of the Board of Trustees of The Darden Foundation, University of Virginia as well as a founding Board member of Choose NJ. Prior to joining Celgene, Mr. Hugin was a Managing Director with J.P. Morgan & Co. Mr. Hugin received an AB degree from Princeton University in 1976 and an MBA from the University of Virginia in 1985 and served as a United States Marine Corps infantry officer during the intervening period. Bob and his wife Kathy live in Summit, New Jersey with their three children.
Dr. Cole serves on the boards of the Liberty Science Center, the American Association of State Colleges and Universities, the Montclair Art Museum, and the New Jersey Performing Arts Center Council of Trustees. She was appointed by Governor Christie as New Jersey’s representative to the Education Commission of the States, and by U.S. Secretary of the Interior Ken Salazar to the Paterson Great Falls National Historical Park Advisory Commission. She served on Governor Christie’s Executive Transition Team and chaired its Education Subcommittee. She also served on the Property Tax Convention Task Force, appointed by Governor McGreevey, as co-chair of his Higher Education Transition Team and on his Education Cabinet, as co-chair of Governor DiFrancesco’s World Class Economy Task Force, and as a member of Governor Whitman’s trade missions to South America and Asia. Dr. Cole earned three degrees in English and American literature: a BA from Barnard College, Columbia University and an MA and PhD from Brandeis University. Dr. Cole writes and speaks extensively about current issues in American higher education.
College of Science and Mathematics Advancing the new skills, approaches, and research critical to the development of tomorrow’s solutions to global health issues Educational Excellence The College of Science and Mathematics (CSAM) has built distinguished academic programs that encompass the natural and physical sciences, computer science, information technology, and K-12 STEM education. With thousands of our alumni employed by the pharmaceutical industry, we continue to promote strong and well prepared graduates in our programs including: • MS in Pharmaceutical Biochemistry and our various BS and MS programs in Chemistry, Biochemistry, and Molecular Biology • New Professional Science Masters in Chemistry and Pharmaceutical Enterprise to start in 2013
Transdisciplinary Discovery In the face of the complex challenges of our 21st century global society, the College of Science and Mathematics engages in strong transdisciplinary approaches to help resolve issues in human and environmental health and sustainability. Through our Margaret and Herman Sokol Institute for Pharmaceutical Life Sciences, and in strong collaboration with the pharmaceutical industry, we promote a diversity of research programs that help explore disease mechanisms and therapeutic approaches for neglected diseases.
Innovative Approaches The College offers creative programs supported by the pharmaceutical industry that reflect the essential needs of innovation and discovery. These programs include both discovery and education through undergraduate research, graduate externships, and STEM education programs for teachers. Science Honors Innovation Program
SHIP Center for Science Teaching and Learning at Montclair State University
MERCK and The ROCHE Foundation
Collaborative Culture CSAM is committed to the ongoing formation of academic/industry collaborations and partnerships to speed the development and commercialization of new technology and provide long-term economic benefits to New Jersey and beyond. That commitment will be fully realized in the new Center for Environmental and Life Sciences, a sophisticated, flexible 100,000 sq. ft. transdisciplinary research facility dedicated to expanding the capacity to generate discoveries and new processes necessary to support the longterm growth of New Jersey’s global health/life sciences industry. Learn how you can become a part of New Jersey’s first university research center designed to meet the challenges of the 21st century by contacting CSAM’s Major Gifts Officer, Peggy Harris, at 973-655-3440 or firstname.lastname@example.org
College of Science and Mathematics Where Discovery and Innovation Meet
Moderators and Panelists Paul Biondi is Senior Vice President of R&D Operations at Bristol-Myers Squibb. As leader of R&D Operations, Mr. Biondi oversees BioPharma Project Management, R&D Resource Management, R&D Strategy and Analytics, R&D Strategic Operations Management, R&D Productivity and Continuous Improvement, and Portfolio & Asset Strategy. He is a member of the R&D Executive Committee as well as numerous other governance bodies within Research and Development.
Christopher Bowe is the US Healthcare Analyst for Scrip Intelligence, an international pharmaceutical news, analysis, and data service. In this position, he creates original and topical analysis for the pharmaceutical and healthcare industries. His work crosses a diverse constituency ranging from industry, and regulators, researchers, to communications and consultancy. Prior to joining Scrip Intelligence, Mr. Bowe served as Counselor, Strategic Affairs at Schering-Plough.
Mr. Biondi joined BMS in 2002 as Executive Director, Global Development Planning & Resource Management and was appointed Vice President of the then newly formed R&D Operations Department in May 2005. This new team was formed to join project management, resource management, performance measurement, and strategic operations functions into one cohesive unit focus on managing the growing complexities of running a global R&D organization. Under his leadership, the responsibilities of R&D Operations have increased to include leadership of R&D’s productivity transformation efforts, oversight of R&D’s portfolio management, and coordination of complex integrations for new acquisitions.
An award-winning writer, previously of the Financial Times, Mr. Bowe also has appeared in print media including Bloomberg, Dow Jones, and Reuters wire services, as well as major broadcast media such as the BBC, Bloomberg TV, CNBC, CNN, Fox Business News, PBS, NPR, and Irish radio.
Mr. Biondi holds a bachelor’s degree in Government and Economics from Dartmouth College and an MBA from J.L. Kellogg School of Management at Northwestern University.
Michel Bitritto is an organic chemist with a track record of transforming research and inventions into profitable businesses. Her career spans from a large multinational chemical, pharmaceuticals and high performance materials corporation to state government and entrepreneurial businesses. Currently, as Director of the New Jersey Meadowlands Commission Business Accelerator, Dr. Bitritto provides early stage companies with support services, guidance and networking opportunities critical to building a profitable science based business. Dr. Bitritto is a past president of the New Jersey Business Incubator Network representing the state’s 12 business incubators which provide critical support services and mentoring to over 500 early stage life science and technology companies throughout the state. She held a leadership position at the New Jersey Institute of Technology Business Incubator where she worked with over 90 entrepreneurial companies. As Associate Director of Business Relations at the New Jersey Commission on Science and Technology in Trenton, she developed funding policies for the state’s investments in its research universities and science and technology businesses. Dr. Bitritto completed post-doctoral research in Chemistry at the University of Maryland, holds a PhD from the University of Connecticut, a masters from the Polytechnic Institute of Brooklyn and an undergraduate degree in chemistry and math from Douglass College, Rutgers University. She sits on many boards in the state including the Advisory Board for the CSAM at Montclair State University.
Brian Cain is Vice President of Global Market Research & Analytics at Merck & Co., Inc. In this role, he has global responsibility for managing the company’s market research function for the Merck pharmaceutical portfolio. Also in his area are Secondary Market Research, Global Analytics, and Forecasting for all products in the Merck pipeline. Additionally, his current focus is on building a global community within the function that drives alignment at the headquarters, regional and country levels to transform the business while optimizing operations. Mr. Cain has more than 25 years of pharmaceutical experience. As past president of the Pharmaceutical Marketing Research Group, he actively participates in working to maintain the integrity of market research. He is the recipient of the 2007 R.R. Fordyce Award and the 2009 Advertising Research Foundation's Great Mind Award. He has been a driving force in the reincarnation of the Pharmaceutical Market Research Group. Mr. Cain received a bachelor’s degree and a Master of Business Administration in Marketing from Saint Joseph’s University in Philadelphia, Pennsylvania.
Jerry Clor has over 30 years’ experience working in the pharmaceutical and biotech environment with four different large and mid-cap companies. He was part of the development team that instituted the first account manager and managed care departments at two different pharma companies. After moving to managed markets, he was responsible for the first dedicated training positions, serving managed care segments. Mr. Clor has been regularly published and has presented at the National Managed Care Congress in Washington DC. He now consults to the bio-pharma industry as well as the provider environment. Mr. Clor received both his BA and his MBA at Stafford University, and his area of focus is managed care, managed markets and reimbursement within the commercial provider marketplace. His current client base includes Genentech, Novo Nordisk, Eisai Pharma, Pfizer, Forest Labs, and Abraxis BioScience.
Moderators and Panelists Terence J. Gunning, currently Chief Operating Officer of MedLabs Diagnostics, a diagnostic testing and services laboratory, has 30 years of management experience in the healthcare industry including diagnostics and services, medical devices, and consumer healthcare products. He is spearheading the transformation of the oldest laboratory in the state of New Jersey into the fastest growing and most advanced boutique laboratory in the tri-state metropolitan market. Prior to MedLabs, Mr. Gunning was CEO of Cadent, a worldwide medical service and device start-up headquartered in Carlstadt, New Jersey. His tenure as CEO of Cadent brought a tripling of revenue and significant improvement in operating profit and cash flow concurrent with several successful capital funding initiatives. As President of Datascope’s Cardiac Assist Division (CA), Mr. Gunning brought significant sales increases, the launch of three new products, CA’s first successful acquisition and reestablishment of CA as the worldwide leader in counter-pulsation therapy. As Vice President and Head of the Corporate Anatomic Pathology Division, and as Vice President, Marketing, for Quest Diagnostics, he led several growth initiatives resulting in significant top- and bottom-line improvements. His resume includes marketing-related senior management positions with Johnson & Johnson Consumer Products and Bristol-Myers Squibb. Mr. Gunning earned an MBA in Finance and Accounting at Columbia University, and holds a BS in Chemistry from Montclair State University.
David Kimball has over 25 years experience in the discovery and development of small molecule drug candidates. He is currently Research Professor at Rutgers University in the School of Pharmacy. Previously, Dr. Kimball was Chief Scientific Officer at Hydra Biosciences, a biopharmaceutical company focused on Transient Receptor Potential (TRP) ion channel drugs pain, inflammation and respiratory disease. Prior to joining Hydra in 2008, Dr. Kimball was Senior Vice President of Research at Pharmacopeia, and was responsible for research alliances, drug discovery research and non-clinical development. Dr. Kimball spent six years at Lexicon Pharmaceuticals in Princeton, New Jersey as Vice President of Medicinal Chemistry beginning in 2001, building an organization of over 75 chemists, including medicinal, analytical, computational, process research and development, library synthesis, and outsourcing chemistry. He spent the first 19 years of his career at Bristol-Myers Squibb in Princeton, New Jersey. He led several significant drug discovery and development research efforts that culminated in clinical compounds, including inhibitors of cyclin-dependent kinase 2, a molecular target in oncology for the treatment of solid tumors, inhibitors of the serine protease thrombin for the treatment of arterial and venous thrombosis, and long-acting calcium channel blockers for the treatment of hypertension and angina. Dr. Kimball has lectured widely on drug discovery and has been an associate member of the graduate faculty at Rutgers University School of Pharmacy since 1989. He earned a PhD in Organic Chemistry/Chemical Biology from the State University of New York at Stony Brook.
Michael Loftus began his career in the clinical space in 2006 when he worked with a small clinical data management shop in Somerset, New Jersey. His previous experiences include Director of Business Development at Worldwide Clinical Trials, Inc., Director of Business Development at XTrials Research Services, Account Manager at ePath Learning and as Business Development at ACSYS. In 2010 he joined Integrium as Director of Business Development. Mr. Loftus holds a BA in Political Science with an emphasis in Business and a masters in Public Administration from West Virginia University. He is very involved with the community and serves as a board member of the Somerset County Planning Board and the local chapter of the American Diabetes Association. He is co-founder of the Rainmakers of New Jersey and chair of the Somerset Young Republicans.
Cheryl Maiello is the Staffing Manager, Global Development for Novartis Pharmaceuticals Corporation. She graduated from Montclair State University in 1997, with a degree in Communications. She was a member of the MSU Field Hockey Team and an Honors Member of Lambda Pi Eta. Mrs. Maiello has been with Novartis since August, 2008 supporting Global Development in staffing. Previously, she was with ImClone Systems and NPS Pharmaceuticals as a Sr. Human Resources Generalist. She is Co-Chair for the Working Parents Connection Employee Resource Group and active participant in other Diversity and Inclusion initiatives. Mrs. Maiello has been married for 9 years and is the mother of two boys, ages 6 and 4.
Avinandan Mukherjee is Professor and Chair of the Marketing Department in the Montclair State University School of Business. Dr. Mukherjee is the Founding Editor-in-Chief of the Emerald journal – The International Journal of Pharmaceutical and Healthcare Marketing. This double-blind reviewed scholarly research journal is dedicated to advancing theoretical and empirical understanding of marketing pharmaceutical products and healthcare services. Before joining Montclair State, Dr. Mukherjee was a full-time faculty member of Marketing at the Pennsylvania State University (USA), University of Bradford (UK), Nanyang Technological University (Singapore) and Indian Institute of Management (India). Dr. Mukherjee’s research and teaching interests include healthcare services, patient compliance strategies, digital healthcare, and pharmaceutical marketing. He has published more than 100 research articles in journals, book chapters, and conference proceedings. Dr. Mukherjee has worked as a consultant with several pharmaceutical and other companies across the world.
Proud Sponsor of
PharmFest 2012 120 Albany Street | Tower 1, Suite 505 | New Brunswick, NJ 08901 | 732-729-9619 www.njlifesciencevendoralliance.com
Francis Cuss was named Senior Vice President, Research, R&D at Bristol-Myers Squibb in May 2010. In this role, he is responsible for the discovery and exploratory development of all potential new medicines at Bristol-Myers Squibb. Dr. Cuss joined Bristol-Myers Squibb in 2003 as Senior Vice President, Drug Discovery, and took over additional responsibility for Discovery Medicine and Clinical Pharmacology in May 2006. He is a physician-scientist. Prior to joining the company, he spent 14 years at Schering-Plough and three years at Glaxo, where his career included assignments in discovery, clinical research and medical affairs in the US and Europe. Prior to joining the pharmaceutical industry, Dr. Cuss was a practicing physician. He has also held several academic appointments, most recently as adjunct associate professor at Jefferson Medical College. Dr. Cuss received his medical training in the UK. He holds medical degrees from Cambridge University and is a fellow of the Royal College of Physicians and of the Faculty of Pharmaceutical Medicine. He has published numerous articles and book chapters on topics of medical interest.
Kalyan Das is Research Professor at the Center for Advanced Biotechnology and Medicine (CABM) and the Department of Chemistry and Chemical Biology, Rutgers University. Dr. Das received his PhD from the Indian Institute of Technology (IIT), Bombay, India. His research interests are in understanding drug resistance, structure-based drug design, viral and bacterial transcription, identification and validation of new drug targets, understanding and targeting protein-protein interactions, molecular modeling and X-ray crystallography.
William J. Greenlee joined Merck Research Laboratories in Rahway in 1977 as a member of the New Lead Discovery department. He was promoted to Director in 1989 and to Senior Director in 1992. In 1995, Dr. Greenlee joined Schering-Plough as Senior Director, Cardiovascular and CNS Chemical Research, and was promoted to Vice President in 2002. He and his group advanced ten drug candidates into clinical trials in a variety of therapeutic areas. After the merger of Schering-Plough with Merck in 2009, Dr. Greenlee served as Vice President of Chemistry and Chemistry Site Head for Kenilworth, and then as Senior Director of Medicinal Chemistry in Rahway. He is now working as an independent medicinal chemistry consultant. Dr. Greenlee has been active in American Chemical Society activities within the Medicinal and Organic Divisions and in other chemistry-related service. He is Perspectives Editor for the Journal of Medicinal Chemistry, and serves on the Editorial Advisory Board for ACS Medicinal Chemistry Letters. Dr. Greenlee has been co-organizer of the annual Drew University Residential School on Medicinal Chemistry since 2002. He received the Alfred Burger Award in Medicinal Chemistry from the ACS in 2004 and was inducted into the ACS Medicinal Chemistry Hall of Fame in 2006. He was elected a Fellow of the American Chemical Society in 2009. He is coauthor of 190 research publications and co-inventor of 60 US patents. Dr. Greenlee received his PhD from Harvard University and was an NIH Post-doctoral Fellow at Columbia University.
The MBA at Montclair State University The School of Business at Montclair State University offers an innovative, market centered Master of Business Administration (MBA) program. The newly redesigned MBA accommodates students with diverse academic backgrounds and features courses in today’s global marketplace. A cohort structure enables students to progress with the same group of classmates, forging long-lasting personal and professional relationships. Other MBA program highlights include: • Apple iPad2 for up-to-date technology and interactive learning • Innovative 1.5 credit courses • Executive speaker series • Seven-to-ten-day international study trip • Small classes taught by top-tier faculty Our MBA programs are offered at our main campus in Montclair, NJ and Brookdale Community College in Lincroft, NJ. This fall we are launching a new weekend-only MBA program conveniently located in Lyndhurst, NJ. This new MBA program is designed for the working professional. Classes are scheduled alternating weekends with holidays off. We are currently accepting applications. For more information, please go to business.montclair.edu/graduate or call us at 973-655-4306.
MBA Office 973-655-4306 • email@example.com • business.montclair.edu/graduate
Moderators and Panelists Donald W. Nicholson is Vice President, Merck Research Laboratories, and Worldwide Discovery Head for R&I (Respiratory & Immunology), based in Kenilworth New Jersey. Prior to taking this role within the newly formed Franchise model, he was Vice President of Immunology and Infectious Diseases, and was Vice President and Site Head of the Merck Neurosciences Research site in San Diego California before that. Dr. Nicholson began his career at Merck at the Merck Frosst Centre for Therapeutic Research in Montreal where he came directly from post-doc training at the Institute for Physiological Chemistry in Munich. His formal training is in biochemistry, cell and molecular biology. Outside of Merck, Dr. Nicholson is internationally recognized for his long-standing contributions to the field of apoptotic cell death pathways, including the initial discovery of the caspases and associated cell death biology. He also holds a crossappointment as Adjunct Professor in the Department of Biochemistry at McGill University in Montreal.
Heidi Pfefferkorn, is currently a Director in the Novartis Pharma Corp Regulatory Chemistry, Manufacturing and Controls group, responsible for supporting large transfer projects in commercial production. She has worked at Novartis Pharmaceuticals Corporation for 19 years, holding positions with increasing responsibility in different departments in drug development. Her experiences include positions in the isotope laboratory, quality, global project management, clinical supplies and regulatory CMC. Ms. Pfefferkorn holds a BS in Chemistry from Montclair State University. She holds a MS in Chemistry from University of Pennsylvania, having studied under Nobel Laureate, Dr. Alan MacDiarmid.
David Rotella is the Sokol Chair of Chemistry and a professor in the Department of Chemistry and Biochemistry at Montclair State University. He holds a BS from the University of Pittsburgh and a PhD from Ohio State University. Dr. Rotella began his career as a postdoctoral scholar at Penn State University, followed by an appointment as Assistant Professor in the Department of Pharmacognosy at the University of Mississippi where in just four years he obtained more than $250,000 in external funding from multiple agencies for his research program. Shortly thereafter, he moved to industry joining Cephalon Inc., Bristol-Myers Squibb, Lexicon Pharmaceuticals and then Wyeth Research (now Pfizer) where he led teams in multiple drug discovery programs. His work has led to an advanced phosphodiesterase inhibitor active molecule in less than one year. He also contributed to the discovery of PDE5 and DPP4 inhibitors that advanced clinical development. Dr. Rotella played a leadership role within the Division of Medicinal Chemistry of the American Chemical Society and served as co-editor of the 7th edition of Burger’s Medicinal Chemistry. He continues to act as senior editor of the Royal Society of Chemistry’s Drug Discovery book series. Dr. Rotella has authored over 30 scientific publications, several books and book chapters, currently holds 7 patents, and has presented more than 30 invited lectures at US universities since 1991 on drug discovery topics.
MaryLinda Schumann earned a BS degree in Chemistry and Biology as well as a Master’s degree in Chemistry from Montclair State University. She began her career in chemistry with a summer QC position at Andrew Jergen’s the summer she graduated from high school and worked part time while matriculating towards her BS degree at a small water treatment company doing boiler water analysis. Upon graduation she began working for Oakite Products, Inc. (now Chemetall US) as an entry level chemist formulating metalworking fluids. Mrs. Schumann has been at Chemetall for almost 34 years. After starting in formulations, she has been involved in many aspects of the business, including development, support (lab and phone), analytical and manufacturing from both a hands on and a management perspective. Mrs. Schumann has had the opportunity to be the recruiter for the company’s internship program for the past eight years. On the personal side, she met my husband in her Chemistry class at MSU. They have two daughters; one is a Montclair State University graduate in Justice Studies and a paralegal. The other has an AAS Degree in Hospitality and is currently at Montclair State working towards a four-year degree in General Humanities.
Sung-Sau So is a Principal Scientist in Computational Chemistry and Datamining Group at Roche, Nutley, New Jersey. He studied chemistry at Oxford University and earned a PhD from Harvard University in 1998. His research interests lie at the interface of theoretical and medicinal chemistry, with particular focus in lead discovery through applications of novel molecular modeling and cheminformatics approaches. His scientific career in drug discovery as a computational chemist includes more than 25 publications and 30 patents, and he has played a key designing role to advance three drug candidates that are currently in human clinical trials.
Sri P Srivastava is Managing Partner at ClinTech Research LLC. He has more than 20 years of experience in drug development including discovery, preclinical toxicology, and clinical operations within the US industry. Prior to founding ClinTech Research, Dr. Srivastava held positions with progressive management responsibilities at large to mid-size multinational pharmaceutical companies such as Parke-Davis (Pfizer), Purdue Pharma, and Organon Pharmaceuticals (Merck). Before joining the pharmaceutical industry, Dr. Srivastava worked as a research scientist at Howard Hughes Medical Institute/University of Michigan, Ann Arbor. He has published more than 20 publications in peer reviewed journals; and has been invited as a speaker at various national and international symposiums. Dr. Srivastava earned his Doctor of Philosophy (PhD) in Biochemistry and his Master of Science (MS) from Banaras Hindu University in India.
Moderators and Panelists Corporate Sustainability: A New Business Model for the 21st Century; and The Going Global Series, a video series that concentrates on a specific country and its developments for US-based businesses to expand. She is a recipient of many awards and accolades in business and holds an MBA from Montclair State University.
Norman Tessell has spent over 25 years in diagnostic imaging serving in both sales, sales management roles with major OEMâ€™s including GE, Toshiba, and Siemens. He is currently Director, Business Development for Atlantis Worldwide, a re-marketer of diagnostic imaging equipment. Mr. Tessell received a BA and MS from the City University of New York and is currently preparing to sit for the Board of Governors exam for Fellowship designation at the American College of Healthcare Executives. He is the Immediate Past President and Board member of the Healthcare Planning and Marketing Society of New Jersey (HPMSNJ), an affiliate of the New Jersey Hospital Association. As chair of the Percy Awards, he heads the group which recognizes the best in healthcare planning, marketing, and public relations for healthcare providers in the state of New Jersey. He is has lectured at the Montclair State University School of Business, and is a reviewer for the International Journal of Healthcare and Pharmaceutical Marketing. In 2010 he, along with Dr. Mukherjee and Dr. Lim initiated the HPMSNJ mentorship challenge for students in the Healthcare and Pharmaceutical Marketing Program for that university.
David Thompson is President of KnowledgePoint360 Group. He joined Gardiner-Caldwell Communications in the UK in 1995. In 2002 he moved to the US to launch what became the Stem Scientific division; he added responsibility for Physicians World in 2006, and for the CodonMedical and BlueMomentum divisions in 2009, with teams based in Secaucus, Chicago, San Bruno, and Macclesfield. Mr. Thompson spent his early career with PricewaterhouseCoopers, then worked as a teacher before entering the medical communications field; his extensive industry experience includes global work for most of the top 20 pharma companies. Mr. Thompson earned a Bachelor of Arts degree in Economics from the University of Newcastle-upon-Tyne and did postgraduate work in education at the University of Manchester.
Sidney Topiol received his BS from CCNY and a PhD from NYU. He trained as a theoretical quantum chemist. He post-docked at Northwestern with Mark Ratner and Arthur Frost, and at Carnegie-Mellon with John Pople (Noble laureate). He first joined The Mount Sinai School of Medicine in the Department of Pharmacology and moved to Berlex and later to Sandoz/Novartis. He has worked on all aspects of Computer Aided Drug Design in interdisciplinary project environments. In 2004 he joined Lundbeck Research, USA as head of US Computational Chemistry and
Structural Investigations. In 2010, he formed 3D-2Drug, a consulting company which provides the means for the most efficient discovery activities through advanced scientific approaches.
Robert Veneziale has over 14 years experience in drug development as a project toxicologist on drug development teams. He has worked on nearly all stages of development from target identification through post-marketing approval. He is currently an Associate Research Fellow in Drug Safety at Pfizer in Pearl River, New York where he works as a Drug Safety Team Lead (DSTL) for oncology and vaccine programs. As a DSTL, Dr. Veneziale is responsible for developing and implementing the nonclinical safety strategy for drug candidates. He presently works on many early stage programs and is responsible for developing de-risking strategies to better understand the potential safety issues of the target. He is also the Drug Safety point of contact for antibody drug conjugates (ADC) and serves as a reviewer for potential in-license programs and technologies. Prior to Pfizer, Dr. Veneziale was a Research Fellow in Toxicology at Merck/Legacy Schering-Plough in Lafayette, New Jersey where he worked for 12 years. At Merck, he worked on a variety of drug programs including small molecules, proteins, monoclonal antibodies and adenoviral gene therapy vectors mainly in mainly oncology and antiinflammation. He was also a study director/monitor for nonclinical toxicity studies and has extensive experience in reproductive toxicology. He earned a PhD in Developmental Biology/Teratology from Thomas Jefferson University in Philadelphia in 1998 and a BS in Biology from Delaware Valley College in Doylestown, Pennsylvania in 1988. Prior to graduate school, he worked for many years at the supervisory and technical level conducting reproductive toxicology studies.
Alan Vernon is Vice President, Translation Plus, a next generation language services provider to the pharmaceutical and healthcare industries. Mr. Vernon is an innovative executive leader and planner with more than 20 years of experience elevating corporate performance and driving profits through the adroit application of consultative sales techniques. He has a recognized ability for delivering account-winning presentations, and building key relationships. Mr. Vernon was born and raised in Texas and is a graduate of Baylor University. He has lived in the New York area for 15 years and resides in upstate New York with his wife and children.
Maria Webb is the Chief Science Officer at Venenum Biodesign, a start-up biotech focused on drug discovery for novel therapeutics in Hamilton, New Jersey. She has worked in the pharmaceutical industry since 1989 when she joined Bristol-Myers Squibb in the Cardiovascular Pharmacology Department. Dr. Webbâ€™s lab focused on G-protein coupled receptors
Moderators and Panelists Cornell Stamoran was named Vice President of Corporate Development and Strategy of Catalent in November 2007. Mr. Stamoran has more than 20 years of experience in the pharmaceutical industry. Since joining Catalent in 1992, he has held many roles across a variety of disciplines, including financial and tax accounting; SEC reporting and financial planning; strategic business and technology planning; sales/business development; market intelligence; corporate development; marketing and branding; innovation; and public and investor relations. Prior to Catalent, he worked at Arthur Andersen & Co. Mr. Stamoran holds a BS degree in accounting and management from the University of Michigan. He is also a certified public accountant (CPA), a certified management accountant (CMA), a certified information systems auditor (CISA), and a certified licensing professional (CLP). Besides being a member of the Association for Corporate Growth, the National Investor Relations Institute, the Society of Competitive Intelligence Professionals, and the World Futures Society, Mr. Stamoran has published articles in a variety of pharmaceutical trade and other publications. He has also served as conference chair and board member for several drug delivery and outsourcing industry conferences.
Terry Richard Stouch is president of Science For Solutions, LLC, a consulting firm specializing in molecular and computational sciences; Senior Editor-in-Chief of the Journal of Computer-Aided Molecular Design; and Adjunct Professor, Department of Chemistry and Biochemistry, Duquesne University. Dr. Stouch has 25 years experience in drug discovery research in large pharma and biotech with specialization in drug design, molecular property prediction, molecular and biomolecular structure, computational sciences, pharmaceutical data evaluation and modeling, and scientific software design. He has participated in placing eight compounds into human clinical trials. He consults for large and small pharmaceutical and biotechnology companies, biomolecular and chemical database organizations, and chemical and biomolecular software companies, among others. He is a Fellow of the American Academy for the Advancement of Science and a Fellow of the International Union of Pure and Applied Chemistry (IUPAC). Previously, Dr. Stouch was Director, Computational Chemistry and Structural Biology at Lexicon Pharmaceuticals; Consultant at the Protein Data Bank; Adjunct Professor, Department of Pharmaceutical Sciences, School of Pharmacy, University of Kentucky; Principal Scientist in Macromolecular Structure at Bristol-Myers Squibb; and an Office of Naval Technology Postdoctoral Fellow at the Naval Research Laboratory. Both his PhD in chemistry and BS in biochemistry were earned at the Pennsylvania State University. He is author of over 70 publications and has presented at over 130 invited lectures.
Suzanne J. Suchard is a Research Fellow in Immunology Drug Discovery at Bristol-Myers Squibb Company in Princeton, New Jersey. Dr. Suchard is responsible for early- and late-phase drug discovery programs, including support of the biological drugs Orencia (abatacept) and Nulogix (belatacept) approved for Rheumatoid Arthritis and Solid-Organ Transplant, respectively. Dr. Suchardâ€™s current research is focused on biologics in the area of T-cell co-stimulation. She is also involved with developing clinical biomarker assays and supports several clinical development programs for the treatment of immune and inflammatory disorders. She earned a BS in biology from the University of Illinois, and a PhD from the University of Maryland in Cell Biology. She was a postdoctoral fellow at the University of Miami School Of Medicine in Pharmacology and Cell Biology and an Assistant/Associate Professor at the University of Michigan School of Medicine in Hematology/Oncology and Cell Biology. She left Michigan to join AstraZeneca Pharmaceuticals in Inflammation Drug Discovery before joining the Bristol-Myers Squibb Company in 2000.
Samir Tari is an inventor and entrepreneur. He was the leading inventor of Polychromatic Angiography and is taking the lead on developing it by starting and running PCAsso Diagnostics LLC. Before PCAsso, Dr. Tari was the medical director with Lux Biosciences, Inc for North America and India. Dr. Tari received his medical training in Cairo University, Egypt followed by several research, translational, and clinical fellowships at Columbia University and the New York Eye and Ear Infirmary in retinal diseases and ocular inflammatory diseases. He is a strong advocate for personalized medicine as he is a founding member of the BioNJ committee for diagnostics and personalized medicine and an active member in the pharmaceutical and biotechnology community in New Jersey in addition to serving as an advisory board member for the Monmouth University School of Science.
Jeanmarie Tenuto is the Chief Executive Officer of Healthcare Technical Solutions (HTS) which opened in 2009. HTS works with medical organizations as they move through the electronic health record transition and is based on the campus of New Jersey Institute of Technology, Newark, New Jersey and part of the Enterprise Development Center, the leading business incubator in the USA. Since 1997, Ms. Tenuto has been in management consulting assisting companies of all sizes, in all industries and all points of the marketing life cycle to adapt to the ever changing landscape. She has worked with over 1600 new businesses through start up and growth phases into maturity, plus trained over 10,000 entrepreneurs, business managers and owners on strategic planning. Her consultative techniques are based on critical thinking skills and understanding the strategies which drive best practices and results. She has authored many articles and books including Smart Selling: How To Move Your Business through a Down-Shifting Market;
The Center for Career Services and Cooperative Education
Montclair State University family – We Can Help PharmFest provides a wonderful opportunity to learn about one of New Jersey’s most important industries. The Center for Career Services and Cooperative Education can help provide you with even more career direction and information, available right at your fingertips with our wide variety of web-based services. Our 24/7 online services give you easy access to valuable career resources, in the comfort of your home. We invite you to take full advantage of all the tools available on our website, www.montclair.edu/CareerServices, including:
Focus 2’s self assessment program, OptimalResume, Vault Company Research, and our online job board, CareerDirections We also encourage you to become a fan of our Facebook page to keep up-to-date with our workshops and campus events! www.facebook.com/RedHawkCareers
1 Normal Avenue • Montclair, NJ 07043 • Morehead Hall, Rm 337 •973-655-5195
Moderators and Panelists (GPCRs) where she and her team worked on several cardiovascular research projects that advanced to the clinic. At BMS, Dr. Webb became interested in the underlying role of inflammation in cardiovascular disease and started working on chemokine and cytokine biology and signaling. In addition to working in â€œbig pharma,â€? Dr. Webb worked for 12 years at Pharmacopeia, Inc., a pioneering company in combinatorial chemistry and high-throughput screening technologies from 1996 to 2008. Dr. Webb and her team implemented this technology to discover leads for collaborators such as Roche, Celgene, ScheringPlough, Organon, GlaxoSmithKline, Daiichi, Takeda, BMS, Wyeth, Pharmacia and Upjohn, Biovitrum, Otsuka, Berlex, and Kowa, among others. Dr. Webb volunteers as a member of SLAS, formerly as a member of the Board of Directors and most recently on the editorial board of Journal of Biomolecular Screening. She consulted for WuXi AppTec in China and for the Mount Sinai School of Medicine Technology Development Fund. She is an advisor to Montclair State Universityâ€™s College of Science and Mathematics, and was an advisor to the Sino-American Pharmaceutical Association in 2000-2002. She also serves as a peer reviewer for journals, and has co-authored 90 papers
Barbara White is the principal of Transformation Coaching & Consulting, LLC. She spent eight years in the pharmaceutical industry in several roles, including North American Human Resources Vice President for Pfizer Consumer Healthcare, and as a Senior Director on the Worldwide Organizational Effectiveness and Consulting Services team for Pfizer Global Pharmaceuticals. Her skills in human resources, organizational development, coaching, and business are broad and deep. Most recently she was the Vice President of Human Resources, North America, for Dun & Bradstreet, and served as the primary architect of their 12-month comprehensive Leadership Development Program. Prior to that, she was with Prudential Healthcare where she was responsible for Diversity and Executive Recruiting, and was the Chief Financial Officer of Group Systems before transitioning into human resources. In addition, her finance career included serving as Chief Financial Officer of Teach for America, multiple finance and accounting roles with Digital Equipment Corporation, and as an auditor with KPMG. Transformation Coaching & Consulting, LLC. addresses individual and workplace issues that are impeding transformation, innovation and success. She draws on over 30 years of professional experience in multiple industries and disciplines as she works with clients to achieve outcomes of enduring value. Ms. White has a MS in Organizational Development from American University, received a BA in Accounting from Rutgers University, and is an inactive Certified Public Accountant. She is also a Coach Core Essentials Graduate of Coach U.
Wayne Wong obtained his BS in Pharmacy degree from Arnold and Marie Schwartz College of Pharmacy (Long Island University). He obtained his Authorized Users license from the USC in 1985. He worked for a publically owned company serving almost 15 years in various roles such as Nuclear Pharmacist, Pharmacy Manager, and Regional Manager. His role was also to be on the Core Business Improvement Committee before the company was sold to Cardinal Health, Inc. Since starting his own nuclear pharmacy in 2000, his role was Nuclear Pharmacist and Vice President of Sales. He has also created new services and solutions to improve use over the past 10 years. Just recently, he became the Senior President for Business Development for Nuclear Diagnostic Products, Inc. Being a visionary in this field, he has also contributed to the proper handling and use for drugs used for non-Hogkins lyphompha as well as liver cancer. He has a particular interest in the integration of molecular imaging as a biomarker into therapeutic drug trails and the use of the molecular imaging in personalized medicine. In 2004, he was awarded the Hall of Fame for the Garden State Society for Certified Nuclear Medicine Technologist. He also spends time volunteering for Habitat for Humanity and a Fundraiser for Avon Walk for Breast Cancer, Heart Walk and Thyroid Cancer.
Pascal Yvon has over 20 years experience in business development on a global basis. Dr. Yvon has worked with startups to mid-sized companies in the life sciences sector. His experience encompasses diagnostics, biotech, and pharmaceutical companies, with a breadth of leadership positions in sales, marketing, project management and general management. Dr. Yvon began his career in France, working with key players in the life sciences industry where he developed business in Europe, Japan, and the US. He has spent the last 12 years in the US where he has been developing business and key relationships in the life sciences industry. As a part of his transatlantic experience, he created commercial organizations, participated in funding road-shows, and developed partnership and distribution agreements. Most recently, Dr. Ivon has been helping life sciences companies develop their business in the US by providing comprehensive services and solutions from strategic planning to operational development and execution. Scope of activities encompasses both business and technical market assessments, market opportunities identification, competitive positioning statement and business plan development, grant submissions, go-to-market strategies, funding, and partnering activities. Dr. Yvon holds a Doctorate in Pharmacy from the Pharmacy University, Paris, and an Executive MBA from Rutgers University. He is a member of BioNJ where he co-chairs the Diagnostics and Personalized Medicine Committee.
ontclair State University and The HealthCare Institute of New Jersey gratefully acknowledge our Corporate and Industry sponsors who provided financial support for PharmFest 2012, as well as the participating support of a number of life sciences, academic, and professionals organizations. All proceeds from PharmFest 2012 will be used for scholarship support, graduate assistantships and student research opportunities to create the pharmaceutical life sciences workforce of tomorrow.
CORPORATE AND ORGANIZATION SPONSORS
PARTICIPATING SPONSORS Atlantis Worldwide BioSciences Expansion, LLC Catalent Chemetall ClinTech Research, LLC Healthcare Technical Solutions Integrium Clinical Research KnowledgePoint360 Group MedLabs Diagnostics Merck New Jersey Meadowlands Commission Business Accelerator
Nuclear Diagnostic Products PCAsso Diagnostics Pfizer Global Research & Development Rutgers University Science for Solutions Scrip Intelligence Translation Plus Transformation Coaching & Consulting Venenum Biodesign 3D-2Drug
PHARMFEST 2012 STEERING COMMITTEE Montclair State Universityâ€™s: Center for Career Services and Cooperative Education College of Science and Mathematics The Margaret and Herman Sokol Institute for Pharmaceutical Life Sciences The School of Business University Advancement The HealthCare Institute of New Jersey
Novartis Pharmaceuticals Corporation congratulates the College of Science and Mathematics and the School of Business at Montclair State University for their continued commitment to academic achievement that goes beyond the sciences. Your efforts in science, research and business are helping to create the pharmaceutical industryâ€™s workforce of tomorrow. From cancer to heart disease to rare disorders affecting smaller populations, Novartis is proud to be the innovative force thatâ€™s bringing new optimism and hope to patients and their families. No one can promise what the future holds for any individual patient, but today millions are winning the fight against their particular diseases, and enjoying life to the fullest.
Todayâ€™s Life Sciences. Tomorrowâ€™s Medicines. What we do in Nutley
At Roche, we believe that finding innovative solutions for serious, unsolved medical problems is what a healthcare company is all about. So, our scientists strive to create clinically differentiated drugs and diagnostic tests to enable tangible improvements in the health, quality of life and survival of patients. Understanding the complex biology of disease is the biggest challenge we face but our scientists are up to the task. At our 127-acre site in New Jersey, one of the largest Roche R&D centers, scientists are developing new medicines for diseases in the areas of oncology, inflammation and virology. All three boast a rich pipeline of novel, first-in-class and best-in-class compounds, which have the potential to improve the health of patients around the world.